We were proud to present EN311, our solution dedicated to the treatment of exocrine pancreatic insufficiency (EPI), to a targeted audience of decision-makers, industry experts, and strategic partners.

– High-quality interactions
– Enthusiastic feedback
– Strong validation of our therapeutic approach

This success further strengthens our commitment to developing and delivering innovative, effective solutions tailored to real clinical needs.

 A sincere thank you to all the Pharmas, Partners & Investors who visited us and showed interest in EN311.

To learn more about EN311, feel free to contact us.